Literature DB >> 15843535

B cell receptor (BCR) cross-talk: IL-4 creates an alternate pathway for BCR-induced ERK activation that is phosphatidylinositol 3-kinase independent.

Benchang Guo1, Thomas L Rothstein.   

Abstract

IL-4 has pleiotropic effects on B cells. These effects include alteration of subsequent BCR-triggered responses. To identify a molecular basis for this receptor cross-talk, we examined ERK activation and NF-kappaB induction. We found that treatment with IL-4, but not other cytokines, affected subsequent BCR signaling by creating a new pathway in which the need for PI3K in ERK activation was eliminated. In contrast, the need for PI3K in NF-kappaB induction was not altered. The new pathway for ERK required time to develop, depended on STAT6, and was blocked by inhibition of macromolecular synthesis. As in the classical pathway, BCR-induced ERK activation in the new, PI3K-independent pathway required MEK and was reflected in c-Raf. Thus, IL-4 promotes an alternate pathway through which BCR is coupled to Raf/MEK/ERK that may function to heighten the responsiveness of B cells during times of immunological stress.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15843535     DOI: 10.4049/jimmunol.174.9.5375

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

Review 1.  Receptor crosstalk: reprogramming B cell receptor signalling to an alternate pathway results in expression and secretion of the autoimmunity-associated cytokine, osteopontin.

Authors:  T L Rothstein; B Guo
Journal:  J Intern Med       Date:  2009-06       Impact factor: 8.989

2.  Signalling of the BCR is regulated by a lipid rafts-localised transcription factor, Bright.

Authors:  Christian Schmidt; Dongkyoon Kim; Gregory C Ippolito; Hassan R Naqvi; Loren Probst; Shawn Mathur; German Rosas-Acosta; Van G Wilson; Athenia L Oldham; Martin Poenie; Carol F Webb; Philip W Tucker
Journal:  EMBO J       Date:  2009-02-12       Impact factor: 11.598

3.  The role of Bruton's tyrosine kinase in the development and BCR/TLR-dependent activation of AM14 rheumatoid factor B cells.

Authors:  Kerstin Nündel; Patricia Busto; Michelle Debatis; Ann Marshak-Rothstein
Journal:  J Leukoc Biol       Date:  2013-06-26       Impact factor: 4.962

4.  Mechanistic Insights into CpG DNA and IL-15 Synergy in Promoting B Cell Chronic Lymphocytic Leukemia Clonal Expansion.

Authors:  Rashmi Gupta; Xiao J Yan; Jacqueline Barrientos; Jonathan E Kolitz; Steven L Allen; Kanti Rai; Nicholas Chiorazzi; Patricia K A Mongini
Journal:  J Immunol       Date:  2018-08-01       Impact factor: 5.422

Review 5.  New insights into pre-BCR and BCR signalling with relevance to B cell malignancies.

Authors:  Robert C Rickert
Journal:  Nat Rev Immunol       Date:  2013-08       Impact factor: 53.106

6.  B cell receptor crosstalk: B cells express osteopontin through the combined action of the alternate and classical BCR signaling pathways.

Authors:  Benchang Guo; Joseph R Tumang; Thomas L Rothstein
Journal:  Mol Immunol       Date:  2008-10-25       Impact factor: 4.407

7.  A novel Lyn-protein kinase Cδ/ε-protein kinase D axis is activated in B cells by signalosome-independent alternate pathway BCR signaling.

Authors:  Benchang Guo; Thomas L Rothstein
Journal:  Eur J Immunol       Date:  2013-04-12       Impact factor: 5.532

8.  The regulation of autoreactive B cells during innate immune responses.

Authors:  Barbara J Vilen; Jennifer A Rutan
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

9.  IL-4 rescues surface IgM expression in chronic lymphocytic leukemia.

Authors:  Benchang Guo; Lu Zhang; Nicholas Chiorazzi; Thomas L Rothstein
Journal:  Blood       Date:  2016-05-25       Impact factor: 22.113

10.  PDK1 regulates B cell differentiation and homeostasis.

Authors:  Gisele V Baracho; Matthew H Cato; Zilu Zhu; Olav R Jaren; Elias Hobeika; Michael Reth; Robert C Rickert
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-16       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.